MENU
FEB 24, 2021 7:30 AM PST

Keynote Presentation: The biomarker to companion diagnostic continuum: a road map for the delivery of precision medicine

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Chief Scientific Officer, Covance Drug Development
    Biography

      Steven Anderson is senior vice president and chief scientific officer for Covance Drug Development. He has worked for LabCorp for 30 years and has held a variety of positions, including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrated Oncology and Integrated Genetics, national director of research and development, and global head of LabCorp Clinical Trials.  His research interests include Molecular Pathology and Oncology based biomarkers, and that work has resulted in the development and validation of multiple companion diagnostics and pharmacogenomic assays in clinical use today. He holds a doctorate in genetics from Iowa State University and was an American Cancer Society postdoctoral fellow at the Waksman Institute of Microbiology at Rutgers University.


    Abstract

    Specific biomarker assays are included in an increasing number of drug labels, with uses ranging from prediction of adverse events to providing insights on efficacy for patient populations.  More than 40 of these biomarkers fit into the category of companion diagnostics, and provide information on the safety and efficacy of the associated therapy.  The ability to develop biomarker assays in a fit for purpose manner, and then translate that development into a companion diagnostic strategy when appropriate is a key element of the delivery of precision medicine.  In this talk, will cover the key elements necessary for the delivery across this continuum of development, including partnership relationships with pharma and diagnostic companies.  Will also cover future trends include expansion of applications to new therapeutic areas, use of multi-analyte technologies and applications, artificial intelligence and machine learning analytics and algorithms, and implementation of new therapeutic modalities such as cell and gene therapies.

    Learning Objectives:

    1. Understanding of the key factors in the development of biomarker assays and requirements for transition to companion diagnostic applications

    2. Examine future technologies and trends that impact the development of biomarker and companion diagnostic assays and their delivery of precision medicine


    Show Resources
    You May Also Like
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAR 16, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    Loading Comments...
    Show Resources
    Attendees
    • See more